Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Venous hypoxia: a poorly studied etiological factor of varicose veins.

Journal of vascular research·2010

Same author

[Cellular mechanisms of regulation of the inflammatory response in atherosclerosis: the role of cell contact-mediated signaling].

Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology·2009

Same author

Adenovirus-mediated VEGF gene therapy enhances venous thrombus recanalization and resolution.

Arteriosclerosis, thrombosis, and vascular biology·2008

Same author

Circulating endothelial progenitor cells as a link between synovial vascularity and cardiovascular mortality in rheumatoid arthritis.

Scandinavian journal of rheumatology·2007

Same author

Migrainous vertigo: prevalence and impact on quality of life.

Neurology·2006

Same author

Activation of NF-kappaB by the intracellular expression of NF-kappaB-inducing kinase acts as a powerful vaccine adjuvant.

Proceedings of the National Academy of Sciences of the United States of America·2006

Search research articles

Related Experiment Video

Updated: Jun 17, 2026

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method

Published on: September 16, 2017

What have we learnt from targeted anti-TNF therapy?

M Feldmann¹, R O Williams, E Paleolog

¹Kennedy Institute of Rheumatology Division, Imperial College, 65 Aspenlea Road, London W6 8LH, UK. m.feldmann@imperial.ac.uk

Annals of the Rheumatic Diseases

|December 10, 2009

Summary

Anti-tumour necrosis factor (anti-TNF) therapy has been used for rheumatoid arthritis since 1992. This review examines anti-TNF knowledge, gaps, and potential cytokine-based treatments for unmet clinical needs.

More Related Videos

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Published on: December 26, 2017

Related Experiment Videos

Last Updated: Jun 17, 2026

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method

Published on: September 16, 2017

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Published on: December 26, 2017

Area of Science:

Rheumatology
Immunology
Pharmacology

Background:

Anti-tumour necrosis factor (anti-TNF) therapy has been a cornerstone in rheumatoid arthritis (RA) treatment since the early 1990s.
Extensive research has elucidated the mechanisms by which anti-TNF agents provide therapeutic benefits in RA patients.

Purpose of the Study:

To review current knowledge and identify existing gaps in understanding anti-TNF therapy for rheumatoid arthritis.
To explore the role of the TNF-dependent cytokine cascade in RA pathogenesis and treatment.
To discuss novel therapeutic strategies, including cytokine analysis, for addressing unmet clinical needs in RA.

Main Methods:

Literature review of studies on anti-TNF therapy in rheumatoid arthritis.
Analysis of the TNF-dependent cytokine cascade and its implications.
Exploration of potential new treatment approaches.

Main Results:

Significant progress has been made in understanding anti-TNF therapy, but knowledge gaps remain.
The TNF-dependent cytokine cascade plays a crucial role in RA.
Cytokine analysis may offer new avenues for treating RA and addressing unmet clinical needs.

Conclusions:

While anti-TNF therapies have advanced RA treatment, further research is needed to address remaining challenges.
Understanding the cytokine network is key to developing more effective and targeted therapies.
Cytokine profiling holds promise for personalized medicine and managing refractory RA cases.